|1.53||+0.0300||+2.00%||Vol 130.75K||1Y Perf 60.91%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||-0.03 -1.96%|
|Target Price||2.50||Analyst Rating||Strong Buy 1.40|
|Potential %||63.40||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/83||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||100/100/-95||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/-80||Income Ranking||— -|
|Price Range Ratio 52W %||25.76||Earnings Rating||Strong Buy|
|Market Cap||75.03M||Earnings Date||7th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.16|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||92.90K|
|Avg. Monthly Volume||233.01K|
|Avg. Quarterly Volume||264.78K|
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) stock closed at 1.53 per share at the end of the most recent trading day (a 2% change compared to the prior day closing price) with a volume of 130.75K shares and market capitalization of 75.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Corvus Pharmaceuticals Inc. CEO is Richard A. Miller.
The one-year performance of Corvus Pharmaceuticals Inc. stock is 60.91%, while year-to-date (YTD) performance is 80%. CRVS stock has a five-year performance of -74.41%. Its 52-week range is between 0.607 and 4.19, which gives CRVS stock a 52-week price range ratio of 25.76%
Corvus Pharmaceuticals Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 0.62, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -44.90%, a ROC of -46.13% and a ROE of -52.98%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Corvus Pharmaceuticals Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. Corvus Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Corvus Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $2.5, which is +63.40% compared to the current price. The earnings rating for Corvus Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Corvus Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Corvus Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.62, ATR14 : 0.14, CCI20 : 92.56, Chaikin Money Flow : -0.06, MACD : 0.03, Money Flow Index : 36.71, ROC : 10.07, RSI : 56.87, STOCH (14,3) : 73.17, STOCH RSI : 1.00, UO : 44.95, Williams %R : -26.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Corvus Pharmaceuticals Inc. in the last 12-months were: Leiv Lea (Buy at a value of $25 639), Richard A. Miller (Buy at a value of $44 827), William Benton Jones (Buy at a value of $15 800)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.